Second, if you are still in the titration phase (the first 16-20 weeks), your dose may not yet be high enough to produce significant weight loss
Researchers can anticipate that the 9mg data will fill the gap between the 8mg and 12mg tiers, potentially identifying an optimal dose that balances efficacy and tolerability better than either existing data point
A: It is the first triple agonist (GLP-1 + GIP + Glucagon) studied in Phase 3 trials
Why We Dont Recommend GLP-1 Patches We do not recommend GLP-1 patches
Abstract Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors
However, Foundayo may be a suitable option for patients who prefer a tablet over injections, those who have difficulty with self-injection or those looking to maintain weight loss achieved through injectable treatment